repevax
sanofi pasteur europe - difteritoksoid / clostridium tetani, toksoid / pertussistoksoid / filamentøst hemagglutinin / kikhostefimbrier type 2 og 3 / pertaktin / poliovirus type 1, inaktivert / poliovirus type 2, inaktivert / poliovirus type 3, inaktivert - injeksjonsvæske, suspensjon i ferdigfylt sprøyte - 2 ie/ dose / 20 ie/ dose / 2.5 mikrog/ dose / 5 mikrog/ dose / 5 mikrog/ dose / 3 mikrog/ dose / 40 d-antigen enheter/ dose / 8 d-antigen enheter/ dose / 32 d-antigen enheter/ dose
ticovac 2.4 mikrog/ sprøyte
pfizer as - skogflåttencefalittvirus (tbe), inaktivert - injeksjonsvæske, suspensjon i ferdigfylt sprøyte - 2.4 mikrog/ sprøyte
ticovac junior 1.2 mikrog/ sprøyte
pfizer as - skogflåttencefalittvirus (tbe), inaktivert - injeksjonsvæske, suspensjon i ferdigfylt sprøyte - 1.2 mikrog/ sprøyte
tetravac
sanofi pasteur europe - difteritoksoid / clostridium tetani, toksoid / pertussistoksoid / filamentøst hemagglutinin / poliovirus type 1, inaktivert / poliovirus type 2, inaktivert / poliovirus type 3, inaktivert - injeksjonsvæske, suspensjon - 30 ie/ sprøyte / 40 ie/ sprøyte / 25 mikrog/ sprøyte / 25 mikrog/ sprøyte / 40 d-antigen enheter/ sprøyte / 8 d-antigen enheter/
viatim 25 mikrog/ dose / 160 e/ dose
sanofi pasteur europe - salmonella typhi vi polysakkarid / hepatitt a-virus, inaktivert - injeksjonsvæske, suspensjon - 25 mikrog/ dose / 160 e/ dose
vaxigrip 15 mikrog/ sprøyte / 15 mikrog/ sprøyte / 15 mikrog/ sprøyte
sanofi pasteur europe - influensa a-virus (h1n1), inaktivert, splittvirus / influensa a-virus (h3n2), inaktivert, splittvirus / influensa b-virus (inaktivert, splittvirus) - injeksjonsvæske, suspensjon i ferdigfylt sprøyte - 15 mikrog/ sprøyte / 15 mikrog/ sprøyte / 15 mikrog/ sprøyte
adcetris
takeda pharma a/s - brentuximab vedotin - lymphoma, non-hodgkin; hodgkin disease - antineoplastiske midler - hodgkin lymphomaadcetris is indicated for adult patients with previously untreated cd30+ stage iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine and dacarbazine (avd). adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following autologous stem cell transplant (asct). adcetris is indicated for the treatment of adult patients with relapsed or refractory cd30+ hodgkin lymphoma (hl):following asct, orfollowing at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option. systemic anaplastic large cell lymphomaadcetris in combination with cyclophosphamide, doxorubicin and prednisone (chp) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (salcl). adcetris is indicated for the treatment of adult patients with relapsed or refractory salcl. cutaneous t cell lymphomaadcetris is indicated for the treatment of adult patients with cd30+ cutaneous t cell lymphoma (ctcl) after at least 1 prior systemic therapy.
allopurinol orion 300 mg
orion corporation - espoo - allopurinol - tablett - 300 mg
allopurinol orion 100 mg
orion corporation - espoo - allopurinol - tablett - 100 mg
allopur 300 mg
orifarm healthcare a/s - allopurinol - tablett - 300 mg